Table 2. Follow-up of subjects included in the survival analysis by retroviral status, Caió, 1989-2009.
| HTLV-1 negative | HTLV-1 positive | |||||||
| HIV neg | HIV-1 pos | HIV-2 pos | HIV-1/2 pos | HIV neg | HIV-2 pos | HIV-1 or HIV-1/2 posa | Total | |
| Number of subjects b | 4,797 | 117 | 285 | 53 | 229 | 69 | 27 | 5376 |
| Lost to follow-up (%) | 161 (3) | - | 8 (3) | - | 6 (3) | 2 (3) | - | 177 (3) |
| Started ART (%) | - | 8 (7) | 12 (4) | 4 (8) | - | - | - | 24 (0.4) |
| Number of deaths (%) | 786 (16) | 43 (40) | 111 (39) | 24 (45) | 73 (32) | 33 (48) | 19 (70) | 1,089 (20) |
| Pyo | 47,986 | 450 | 2,680 | 272 | 2,003 | 568 | 113 | 54,071 |
| MR per 100 pyo (95% CI) | 1.6 (1.5–1.8) | 9.6 (7.1–12.9) | 4.1 (3.4–5.0) | 8.8 (5.9–13.1) | 3.6 (2.9–4.6) | 5.8 (4.1–8.2) | 16.9 (10.8–26.4) | 2.0 (1.9–2.1) |
| Crude MRR (95% CI) | 1 | 5.8 (4.3–7.9) | 2.5 (2.1–3.1) | 5.4 (3.6–8.1) | 2.2 (1.8–2.8) | 3.5 (2.5–5.0) | 9.8 (6.2–15.5) | - |
Neg, negative; pos, positive; ART, Anti-retroviral treatment; Pyo, person-years of observation; MR, mortality rate; MRR, mortality rate ratio; CI, confidence interval.
a
10 subjects were HTLV-1/HIV-1 infected (of which 5 died) and 17 were HTLV-1/HIV-1/2 infected (of which 14 died).
b
subjects that seroconverted contribute to different columns.